tracken
AnaptysBio, Inc. Aktie News
Negativ
Investors Business Daily
●
etwa 23 Stunden alt
AnaptysBio stock buckled Friday after the biotech company and GSK filed competing lawsuits against one another over a licensing deal.
Negativ
Reuters
●
etwa 24 Stunden alt
Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's GSK , filed lawsuits against each other, with both claiming a breach in a partnership deal for a cancer drug.
Negativ
WSJ
●
ein Tag alt
The companies accuse one another of breaching a licensing agreement for Jemperli, a drug used to treat some forms of endometrial cancer.
Neutral
GlobeNewsWire
●
ein Tag alt
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized an amended Stock Repurchase Plan under which the Company may repurchase up to $100.0 million of the Company's outstanding common stock, par value $0.001 per share....
Neutral
GlobeNewsWire
●
ein Tag alt
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a Verified Complaint in Delaware Chancery Court, requesting a court declaration that TESARO, Inc. (“Tesaro”) has materially breached the parties' Collaboration and Exclusive License Agreement (“Colla...
Negativ
Proactive Investors
●
ein Tag alt
GSK PLC (LSE:GSK, NYSE:GSK) has stepped up a dispute over rights to its fast-growing cancer drug Jemperli by having its US subsidiary Tesaro sue AnaptysBio in the Delaware Court of Chancery. Tesaro is asking the court to confirm that alleged breaches of their 2014 licence deal allow it to end the current contract, keep a perpetual licence to the medicine and cut by half the royalty and mileston...
Neutral
Seeking Alpha
●
9 Tage alt
AnaptysBio receives a "Hold" rating after discontinuing rosnilimab for ulcerative colitis, saving $10 million but maintaining focus on rheumatoid arthritis. ANAB plans to advance rosnilimab for RA, with a program update expected in the first half of 2026, seeking non-dilutive funding or a strategic partner. Development of CD122 antagonist ANB033 for Celiac Disease continues in phase 1b, targeti...
Negativ
Investors Business Daily
●
12 Tage alt
AnaptysBio stock plummeted Monday, reversing a recent run, after its experimental ulcerative colitis drug failed in midstage testing.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
